Cargando…

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts

RESEARCH BACKGROUND: Currently, multiple myeloma is the second most common hematological malignancy in the U.S., constituting 1% of all cancers. With conventional treatment, the median survival time is typically 3–4 years, although it can be extended to 5–7 years or longer with advanced treatments....

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Minna, Wu, Dan, Carey, Michelle, Zhou, Xiaobo, Zhang, Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676611/
https://www.ncbi.nlm.nih.gov/pubmed/26659358
http://dx.doi.org/10.1371/journal.pone.0143206